Henry Ford Hospital Medical Journal
Volume 4 | Number 4

Article 2

12-1956

New Methods Of Deleading Heavy Lead
Absorption Using Calcium Mono Sodium
Ethylene Diamine Tetra Acetate (EDTA)
Elston L. Belknap

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health
Commons
Recommended Citation
Belknap, Elston L. (1956) "New Methods Of Deleading Heavy Lead Absorption Using Calcium Mono Sodium Ethylene Diamine
Tetra Acetate (EDTA)," Henry Ford Hospital Medical Bulletin : Vol. 4 : No. 4 , 210-213.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol4/iss4/2

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry
Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact
acabrer4@hfhs.org.

NEW METHODS OF DELEADING HEAVY LEAD ABSORPTION
USING CALCIUM MONO SODIUM ETHYLENE
DIAMINE TETRA ACETATE (EDTA)*
ELSTON L . BELKNAP, M.D.**

After dealing with this subject for thirty years, I still find new and unexpected
types of lead exposure, non-industrial as well as industrial. In all cases the dosage,
that is, concentration and duration of exposure, is important. For my own understanding
and for that of others, each case should be analyzed from the point of view of lead
absorption as distinct from lead intoxication. Evidence of lead absorption is shown
by the demonstration of lead line, a few stippled cells 5 to 10 per fifty fields, coproporphyrin in the urine, and, when medical-legal need demands it, quantitative study of
lead in the urine. These findings do not, however, necessarily spell lead poisoning.
Lead poisoning or lead intoxication occurs only when, in addition to the above
mentioned findings of lead absorption, we have symptoms or signs of actual disability.
These symptoms may be merely weakness due to a secondary anemia usually preceded
by a rapidly rising stippled cell curve. Lead intoxication occurring in 90 per cent of
the cases is that of typical abdominal lead colic associated with ever-increasing constipation. As a positive therapeutic test and in contrast to the acute surgical belly, such a
lead colic is relieved rapidly by intravenous calcium gluconate. Lead palsy which occurs
only one-tenth as often as lead colic is the second commonest type of lead intoxication.
Treatment for this in the past has been rest of the affected part for several months.
The rarest type of lead intoxication in adults is lead encephalopathy. In children,
however, it is the most common type and seems to be increasing. In the past, treatment
has not been specific for lead encephalopathy in the child. In the majority of cases,
the outlook has been poor, frequently resulting in death or a serious residual in the
form of mental deterioration. However, with increased use of Calcium EDTA the
outlook has apparently improved.
In the treatment of the commonest type of lead intoxication in the adult, namely,
the lead colic, there are two aims (1) the immediate relieve of symptoms, and (2)
ridding the system of absorbed lead by some type of deleading therapy after the acute
symptoms have subsided. I f we were merely scientific we would simply remove the
individual from lead exposure, knowing that within a week or two the lead colic
symptoms would subside spontaneously. However, such a strictly scientific form of
therapy is inadequate.
Since introduced by Joseph Aub in 1926 calcium salts have been efficacious when
given intravenously for the rehef of lead colic. However, such relief by calcium
gluconate seems to be due to the non-specific effect of calcium in relaxing smooth
muscle, rather than an immediate clearing away of the lead by the calcium.

*Presented before the Henry Ford Hospital Medical Association, Detroit, Michigan, Nov. 12, 1954.
**Associate Clinical Professor of Medicine, Marquette University School of Medicine, Milwaukee,
Wis. Formerly, Resident, Department of Medicine Henry Ford Hospital.

210

For actually ridding the system of absorbed lead by deleading there have been
many different types of therapy suggested in the past 25 to 30 yearl Clinicians have
advocated shift of the acid-base metabolism, low calcium intake, high phosphorous
diet with magnesium sulphate sodium citrate, and the long used potassium iodine
type of therapy. However, no single method has been completely satisfactory A l l have
been questioned by a number of workers in the field. Certainly no such general agreement upon treatment for deleading exists as does for the relief of smooth muscle colic
by calcium gluconate. Calcium Mono Sodium Ethylene Diamine Tetra Acetate, also
called Calcium EDTA, Versene or Sequestrine, recently introduced, may be the deleading agent when given intravenously. Certainly it increases the urinary lead excretion
markedly. To show how effective this new drug is in stimulating urinary lead
excretion, we need only to note the previous levels in acute lead intoxication of
about .3 to .8 mgs. lead per liter of urine lead, now raised 10 to 20 times this old
excretory figure.
Let me emphasize that we are discussing the use of Calcium EDTA, not Sodium
EDTA. Calcium EDTA seems to be harmless, though the sodium salt in much heavier
dosage than I have used may produce a lower nephron nephrosis. Detailed blood
chemistry and bone marrow studies of my hospital series showed no toxic effects from
the Calcium EDTA except a slight transient bone marrow depression in 2 of 7 cases.
In California, experimental work is being done as to possible toxicity of Calcium EDTA.
Publications on this subject began to appear about 1950. Reports on the subject
from individuals and medical centers throughout the country have been increasing
especially since 1952 and number about 80.
The theory of action of this new drug. Calcium EDTA, is that it chelates or binds
a metal-ion like lead by complexing the metal in a ring structure so tightly that it is
un-ionized. This apparently renders the metal harmless for safe excretion. Whether,
however, such complexing will cause immediate relief of symptoms such as actual'
lead colic is still an open question. We do know that it is the most effective from of
deleading that has yet been discovered either in the acute type of lead intoxication
or the chronic type of lead absorption.
My hospital cases were treated with 5 cc. intravenously or one gram of Calcium
EDTA diluted in 250 cc. of 5% glucose in distilled water over a period of 20 minutes
twice a day for five days followed by a rest period of two days with a resumption of
the five day course. This was followed by an additional period of rest for two days
and finally a course of four days as before. Uniformly lead excretion went up and
porphyrinuria went down. Some feel that this latter finding is most important because
it may be an index of improved liver function slides.
My own experience covers about twenty cases in whom I used Calcium EDTA
intravenously. Seven of these were under hospital control and showed no lasting
residual. Thirteen outpatients who were workers having heavy lead absorption but no
evidence of any disabling lead intoxication, were also studied. They were treated
on a purely prophylactic and preventive basis supplemented by the reduction of lead
exposure by increased engineering protective techniques installed by plant management.
These 13 cases of extremely heavy lead absorption followed intense lead exposure due
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to their work in smelting scrap battery plates. It was a small plant where engineering
protection had, at that time, been entirely inadequate. It then seemed that the men
would either have to be laid-off or hospitalized. Inasmuch as they had no symptoms,
and management promised marked improvement in engineering protection, I felt it
advisable to treat them intravenously with Calcium EDTA. A l l were given one to four
courses of Calcium EDTA intravenously on the following modified schedule while at
work and without symptoms. The men were sent to the company doctor's office one
hour each day for five days a week. During the first part of the hour each man was
given intravenously 5 cc. of Calcium EDTA in 250 cc. of 5% glucose in normal saline
over a period of 20 minutes. He rested one-half to three-quarters of an hour and then
returned to work. At no time did any man show untoward symptoms, and all insisted
they felt better. The lead lines of the gums disappeared, and the slipped cells dropped
markedly. Because these cases were studied while at work and were not under hospital
control, it was impossible to study their 24 hour urine excretion. However, their urine
porphyrin dropped rapidly and continued low just as in the 7 cases studied under
hospital control.
In summary, these clinical cases seem to show that Calcium EDTA given intravenously is an excellent method of ridding the organism of lead by deleading, though
in my experience it does not relieve lead colic promptly. My studies as well as other
reports in the literature prove it to be superior to any previous deleading treatment
and entirely safe.
One recent and detailed report of three cases treated with Calcium EDTA at the
Massachusetts General Hospital, is that by Hardy'. A l l of Dr. Hardy's cases were
subsiding lead intoxication, lead colic type cases, whereas two of mine were actually
having acute lead colic. My experience in these two cases, moreover, tends to suggest
that the intravenous Calcium EDTA will not relieve lead colic at once, though it
certainly increases the urinary lead excretion. Immediate relief of symptoms can,
therefore, be best obtained by supplementary calcium gluconate given intravenously in
alternate doses with the Calcium EDTA.
Whether or not Calcium EDTA may be used prophylactically in the form of
tablets for oral use in the cases of heavy lead absorption remains to be studied further.
Such oral therapy is certainly not as effective as the intravenous form.
Experience in these 7 cases of heavy lead absorption treated under hospital control
and the 13 cases treated in the doctor's office while at work, indicates that the intravenous Calcium EDTA is both effective and safe as a deleading agent. However, this
is to be considered an emergency measure. Proper engineering protective devices which
prevent lead exposure and resultant lead absorption are still the best treatment.
A D D E N D U M September 10, 1956.
A detailed report of the 7 hospital cases referred to in this paper was presented
before the American Medical Association June 22, 1954 and published in December
1954^
Since this time a number of other individuals have reported cases treated with
Calcium EDTA with prompt and effective elimination of lead. However, Foreman^ has
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recently reported a case of a patient heavily loaded with plutonium whom he had
treated with Calcium EDTA. He sounds a note of warning regarding nephrotoxic
hazard from uncontrolled Edathamil Calcium-Disodium therapy. After a preliminary
5 gm. treatment of 4 days followed by two days rest, the drug was administered for
another 12 consecutive days. This is definitely a more concentrated type of therapy
than I have recommended. However, because plutonium is apparently more difficult
to remove from the body than is lead, this therapy seemed necessary. His patient
then showed evidence of apparent damage to the renal tubules though this was fortunately reversible.
Foreman then did further experimental work on rats treated daily for 16 days
which led him to believe that 2.5% of patients given 9 grams of the drug a day for
16 days would be expected to develop nephrosis. However, he recommends the
therapeutic dosage level of 5 grams a day given not more than 5 days in succession
and followed by a two-day rest period as well within the desirable safety limits. The
dose of 2 grams a day that I have used and found successful seems safe in the individual
who does not already have evidence of acute or chronic renal disease.
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